



SINCLAIR PHARMA PLC

Sinclair Pharma Licenses Xclair™ in Brazil and Portugal

Godalming UK, 7 July, 2005: Sinclair Pharma plc (“Sinclair” or the “Company”) (SPH.L), the specialty pharmaceutical company, announces two new sales and marketing agreements for Xclair™, its product for the treatment of radiation dermatitis. Radiation dermatitis is a common side effect of radiotherapy for the treatment of cancer.

Under the terms of the Xclair™ agreements, the product has been exclusively licensed to Pharmis Group for sale in Portugal and in Brazil. Pharmis Group focuses on the marketing and sales of pharmaceutical products exclusively to the hospital market place. Pharmis plans to market Xclair™ through its focused, specialty oncology sales representatives through the major treatment centres in Portugal and Brazil. The marketing strategy will aim to increase awareness of the benefits of Xclair™ in treating the debilitating effects on the skin of radiation dermatitis. These 10 year agreements include license fees and minimum sales commitments.

Dr Michael Flynn, CEO of Sinclair, said: “We now have marketing and sales agreements in place for Xclair™ in eight territories including the US. In the absence of any clear established brand for the treatment of radiation dermatitis we believe that Xclair™ will be welcomed as an effective topical product in cases where radiation therapy causes inflammation and discomfort of the skin and we hope to create a global brand.”

Antonio Barbosa , Chairman and Chief Executive Officer of Pharmis, added:

“We are delighted that Sinclair recognizes Pharmis as its partner of choice in bringing this exciting product to market in our home market of Portugal as well as in one of the major developing pharmaceutical markets in South America.

“Xclair™ will expand our presence in the hospital-based setting, consistent with our strategy of growing our franchise in oncology and complementary therapies. There is a significant unmet need for an effective treatment for this condition and we are excited about the prospect of marketing Xclair™ which represents a major advance in the treatment of radiation dermatitis.”

END

Enquiries:

Sinclair Pharma plc

Dr Michael Flynn, CEO

John Barrington-Carver (Corporate PR)

Tel: 01483 426 6444

Tel: 07831 655 630

Financial Dynamics

Ben Atwell or Lucy Briggs

Tel: 0207 831 3113

MORE

Notes to editors:

Sinclair Pharma plc

Sinclair Pharma plc based in Godalming in the UK, is quoted on the Alternative Investment Market (AIM) on the London Stock Exchange and has focused on the acquisition and development of niche patented pharmaceutical products in the fields of oral health, oncology support and dermatology, and bringing them to the international market place via out-licensing partners. The Company combines product evaluation, product development, regulatory and business development expertise to add value to its acquired and in-house developed products. A key element of the Sinclair business model is to minimise risk and exposure by avoiding involvement in lengthy R&D programmes and rapidly achieving global distribution through a network of marketing partners. The Company has already licensed its products for distribution in over 40 countries around the world.

www.sinclairpharma.com

Pharmis

Pharmis is a specialty marketing and distribution company based in Portugal with subsidiaries in Brazil and Spain. The company, established in 1991 focuses on hospital products in oncology, pulmonology and critical care medicine. Pharmis has agreements with partners of assured quality such as Skyepharma, Doblar, CellPep, Nexpharma and Sterilyo-GSK.

Brazil represents the 9th largest pharmaceutical market and accounts for 40% of the Latin American market.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.